SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

Recruiting now

Conditions studied: Myocardial Infarction, Diabetes Mellitus, Type 2

In brief

Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction. The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.

Key facts

Study ID

NCT05770687

Run by

Kiyuk Chang

People needed

1000

Starts

2020-08-01

Expected to finish

2026-12-31

Last updated by the study team

2025-01-03

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Acute myocardial infarction who were treated with percutaneous coronary intervention
• Type 2 diabetes mellitus
• Started SGLT2 inhibitors <1 month before/after PCI

You may not qualify if…

• Type 1 diabetes mellitus
• Insulin / GLP-1 analogue users
• Previous users of SGLT2 inhibitors
• Pregnancy

Where it is running

• Seoul St. Mary's Hospital — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.